Condensed Consolidated Statements of Changes In Temporary Equity And Permanent (Deficit) Equity - USD ($) $ in Thousands	Total	Redeemable Noncontrolling Interest[Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Common Class A [Member]	Common Class A [Member] Common Stock [Member]	Common Class B [Member] Common Stock [Member]	Class A Ordinary Shares Common Stock [Member]	Class B Ordinary Shares Common Stock [Member]
Beginning Balance at Dec. 31, 2020	$ 9,864			$ (0)	$ (106,364)		$ 115,000	$ 1,228
ProKidney Corp. Class B ordinary shares at Dec. 31, 2020							115,000,000
Capital contribution, Shares							71,500,000
Capital contribution	71,500						$ 71,500
Equity-based compensation	699							699
Net Income (Loss)	(55,146)				(55,146)	$ (55,146)
Repurchase of Class A ordinary shares Amount	0
Exchange of Class B ordinary shares for Class A ordinary shares Value	0
Net loss and comprehensive loss attributable to noncontrolling interest	0
Ending Balance at Dec. 31, 2021	26,917			(0)	(161,510)		$ 186,500	1,927
Ending Balance (in shares) at Dec. 31, 2021							186,500,000
Capital contribution	6,050							6,050
Equity based compensation after the Business Combination	7,155	$ 6,150	$ 7,155
Net Income (Loss)						(108,032)
Net loss prior to the Business Combination	(93,632)			(0)	(93,632)
Effect of Business Combination, Shares							(186,500,000)		61,540,231	170,723,961
Effect of Business Combination, Value	(1,092,694)	1,635,829		(0)	(834,574)		$ (186,500)	(71,644)	$ 6	$ 18
Equity-based compensation / payments prior to Business Combination	63,667							$ 63,667
Vesting of Class B restricted stock rights, Shares										854,359
Repurchase of Class A ordinary shares Amount	0
Exchange of Class B ordinary shares for Class A ordinary shares Value	0
Net loss after the Business Combination	(14,400)	(40,103)		(0)	(14,400)
Change in redemption value of noncontrolling interest	0
Impact of equity transactions on redeemable noncontrolling interest	321	(321)	321
Net loss and comprehensive loss attributable to noncontrolling interest	(40,103)
Ending Balance at Dec. 31, 2022	(1,096,616)	1,601,555	7,476		(1,104,116)				$ 6	$ 18
Ending Balance (in shares) at Dec. 31, 2022									61,540,231	171,578,320
Equity-based compensation	23,841	7,005	23,841
Issuance of Class A ordinary shares									50,000
Net Income (Loss)	(35,468)				(35,468)	$ (35,468)
Vesting of Class B restricted stock rights, Shares										2,266,079
Repurchase of Class A ordinary shares Amount	(9,499)		(9,498)						$ (1)
Repurchase of Class A ordinary shares									(7,256,367)
Exchange of Class B ordinary shares for Class A ordinary shares Value	9,500	(9,500)	9,500						$ 1	$ (1)
Exchange of Class B ordinary shares for Class A ordinary shares									5,546,483	(5,546,483)
Change in redemption value of noncontrolling interest	(79)	79			(79)
Impact of equity transactions on redeemable noncontrolling interest	4,795	(4,795)	4,795
Unrealized loss on marketable securities	130	367		130
Net loss and comprehensive loss attributable to noncontrolling interest	(99,979)	(99,979)
Ending Balance at Dec. 31, 2023	$ (1,103,396)	$ 1,494,732	$ 36,114	$ 130	$ (1,139,663)				$ 6	$ 17
Ending Balance (in shares) at Dec. 31, 2023									59,880,347	168,297,916